Israel refines psychedelic drugs for treating neurological disorders

The Israeli company Nextage Therapeutics has developed technology that it believes could enable the refined use of hallucinogens to treat people with neurological disorders. The technology would allow for the necessary dosage to be reduced, which in turn would potentially reduce many of the side effects and risks associated with use of psychedelic drugs such as ibogaine.